Distinct Roles for Leukemia Inhibitory Factor Receptor alpha -Chain and gp130 in Cell Type-specific Signal Transduction*

(Received for publication, May 5, 1997)

Robyn Starr Dagger , Ulrike Novak §, Tracy A. Willson Dagger , Melissa Inglese , Vincent Murphy , Warren S. Alexander Dagger , Donald Metcalf Dagger , Nicos A. Nicola Dagger , Douglas J. Hilton Dagger par and Matthias Ernst **

From the Dagger  Cooperative Research Centre for Cellular Growth Factors and the Walter and Eliza Hall Institute for Medical Research, the § Department of Medicine, University of Melbourne, and the  Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Victoria 3050, Australia

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Leukemia inhibitory factor (LIF) induces a variety of disparate biological responses in different cell types. These responses are thought to be mediated through the functional LIF receptor (LIFR), consisting of a heterodimeric complex of LIFR alpha -chain (LIFRalpha ) and gp130. The present study investigated the relative capacity of the cytoplasmic domains of each receptor subunit to signal particular responses in several cell types. To monitor the signaling potential of LIFRalpha and gp130 individually, we constructed chimeric receptors by linking the extracellular domain of granulocyte colony-stimulating factor receptor (GCSFR) to the transmembrane and cytoplasmic regions of either LIFRalpha or gp130. Both chimeric receptors and the full-length GCSFR in expressed in M1 myeloid leukemic cells to measure differentiation induction, in embryonic stem cells to measure differentiation inhibition, and in Ba/F3 cells to measure cell proliferation. Our results demonstrated that whereas GCSFR-gp130 receptor homodimer mediated a GCSF-induced signal in all three cell types, the GCSFR-LIFRalpha receptor homodimer was only functional in embryonic stem cells. These findings suggest that the signaling potential of gp130 and LIFRalpha cytoplasmic domains may differ depending upon the tissue and cellular response initiated.


INTRODUCTION

A characteristic feature of cytokines such as leukemia inhibitory factor (LIF)1 is their ability to regulate a wide range of biological activities (1). The diverse effects of LIF include both stimulation and inhibition of cellular proliferation (2, 3) and activation of cell type-specific gene expression (4). LIF also induces macrophage differentiation in M1 myeloid leukemia cells (5), whereas it elicits an opposite effect in embryonic stem (ES) cells, maintaining these cells in an undifferentiated, pluripotent state (6, 7).

In addition to functional pleiotropy, the biological actions of LIF and related cytokines, such as interleukin (IL)-6, IL-11, oncostatin M (OSM), cardiotrophin-1, and ciliary neurotrophic factor (CNTF), are largely overlapping. The common activities of the LIF family of cytokines have been attributed in part to the existence of multimeric receptors, which share the affinity converting and signal transducing subunit, gp130 (8-11). These receptors can be divided into three distinct types (12). First, LIF, OSM and cardiotrophin-1 each use receptors consisting of a heterodimeric complex of gp130 with the LIF receptor alpha -chain (LIFRalpha , sometimes known as LIFRbeta ). In addition, OSM has been shown to signal through an alternative receptor complex, consisting of a heterodimer of a ligand-specific subunit (OSM receptor beta -chain) and gp130 (13). Second, CNTF binds to a ligand-specific subunit (CNTF receptor alpha -chain), which associates with a heterodimer of LIFRalpha and gp130. In contrast, functional IL-6 and IL-11 receptors are formed by the association of ligand-bound alpha -chains with gp130 homodimers, with no involvement of LIFRalpha . Unlike the ligand-binding components of the IL-6, IL-11, and CNTF receptors, which do not contribute to intracellular signaling, LIFRalpha contains an extensive cytoplasmic domain with a structure similar to both gp130 and the GCSFR (14).

The separate contributions of the LIFRalpha and gp130 cytoplasmic domains to LIF-induced signal transduction have not been investigated in detail. Although it has been established that mutant LIFRalpha lacking a cytoplasmic domain is inactive (15), its relative capacity compared with gp130 for triggering diverse biological outcomes is less well established. Both receptor subunits have the ability to associate with and activate the Janus kinases Jak1, Jak2, and Tyk2 as well as several other tyrosine kinases (16), suggesting that common signaling pathways may be triggered by each receptor component (17). Despite their molecular similarity, it is possible that the two receptor chains are not functionally equivalent, with one subunit having a greater potential to transduce particular responses. Differences in the signal transduction pathways triggered by LIF-related cytokines have been implicated by previous studies (18, 19), in which enforced expression of the SCL transcription factor in M1 cells reduced the ability of these cells to differentiate in response to LIF and OSM (signaling through LIFRalpha -gp130 heterodimers) but not IL-6 (signaling through gp130 homodimers).

In the present study, we investigated the relative potential of LIFRalpha , gp130, and GCSF receptor chains to signal cell type-specific responses. For this purpose, we expressed chimeric receptor constructs that comprised the extracellular domain of GCSFR and the transmembrane and cytoplasmic regions of either LIFRalpha or gp130. This approach enabled us to drive GCSF-dependent homodimerization of chimeric receptor subunits independently of endogenous receptor chains. The validity of this strategy had been established by previous studies (20, 21), including those demonstrating that human hepatoma cells expressing similar chimeric receptors acquired GCSF responsiveness (15, 22). Our results demonstrate that the signaling potential of LIFRalpha , gp130, and GCSFR homodimers varies in different cell types, with LIFRalpha homodimers playing an active role in suppressing ES cell differentiation but having a reduced potential to induce macrophage differentiation compared with either gp130 or GCSFR homodimers.


EXPERIMENTAL PROCEDURES

Cell Culture and Cytokines

M1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FCS). Ba/F3 cells were cultured in RPMI 1640 medium supplemented with 10% FCS and 10% WEHI-3B D- conditioned medium as a source of IL-3. The ES cell lines, derived from the parental line E14TG2a, which contains a null mutation in the hypoxanthine-phosphoribosyl transferase gene (hprt-; Ref. 23), were passaged in ES cell medium (DMEM containing 15% FCS, 0.1 mM 2-mercaptoethanol, and 1000 units/ml LIF) in the absence of feeder cells. Recombinant murine LIF was produced in Escherichia coli and purified as described previously (24). Purified recombinant human GCSF, used for all biological assays, was the gift of AMGEN, and purified recombinant IL-3 was purchased from PeproTech Inc. (Rocky Hill, NJ). Mouse GCSF was produced in Pichia pastoris (25), purified, and then iodinated for use in binding assays.

DNA Constructs

Chimeric receptors were constructed by cloning the HindIII-XbaI fragment of the murine GCSFR (26) into pBLUESCRIPT (SK)+. A silent mutation was then introduced at nucleotide +2045, to create a BamHI restriction enzyme site near the start of the transmembrane region (pBS/mGR(Bam)). BamHI sites were also introduced into murine gp130 at position +1851 and in human LIFRalpha (14) at position +2489 by nucleotide substitution in the region immediately preceding the transmembrane domain of each molecule. Expression constructs were generated by annealing the BamHI site of the GCSFR extracellular domain with the transmembrane/cytosolic domain of either gp130 or LIFRalpha (construct 1) and ligating the chimeric receptor cDNA into the SalI site of the expression vector 6P-IRESneo-BS, driven by a PGK promoter (27). An additional GCSFR-LIFRalpha construct (construct 2) was generated by polymerase chain reaction amplification of a fragment of the human LIFRalpha cDNA containing the transmembrane and cytoplasmic regions. Polymerase chain reaction primers contained an in-frame BamHI site at the 5' end (5'-ACGTGGATCCATCTGACGTGGGATTAATTATTGCCATT-3') and an XbaI site at the 3' end (5'-AGCTTCTAGACTGTTAATCGTTTGGTTTG-3'). This fragment was then inserted into BamHI-XbaI digested pBS/mGR(Bam). The GCSFR-LIFRalpha fragment was released by digestion with HindIII and XbaI, and the ends were filled in with Klenow (Promega) and ligated into the expression vector pEF-BOS (28) using BstXI adaptors (Invitrogen). Although the two GCSFR-LIFRalpha constructs differed slightly, because construct 1 contained a Pro right-arrow Leu substitution at amino acid 599 and a deletion of amino acid 601 at the 3' end of the GCSFR extracellular domain, no difference between the constructs was observed in a colony assay in the presence of GCSF following stable transfection of M1 cells. Similarly, ES cells were transfected with both constructs, and expression of either construct was found to confer a GCSF-responsive phenotype in these cells. The sequence of all chimeric constructs was verified using an ABI PRISM Dye Terminator Cycle Sequencing Kit (Perkin-Elmer) and a model 373 Automated DNA Sequencer (Perkin-Elmer). cDNA encoding the full-length human GCSFR (a gift from S. Nagata, Osaka Bioscience Institute) was cloned into the XbaI site of the pEF-BOS expression vector. The pHCK-hprt plasmid was created by substituting the PGK promoter in the PGK-hprt expression cassette of pGEM-7Z with an XhoI-BamHI fragment of the murine hck promoter, encompassing the region between -645 and +240 relative to the major transcription initiation site (29).

Stable Transfection of Cell Lines

M1 and Ba/F3 cells were transfected with plasmids expressing either full-length GCSFR, GCSFR-LIFRalpha (construct 2), or GCSFR-gp130 by electroporation, essentially as described (11). Receptor constructs were cotransfected with the pPGKPuropA expression vector (kindly provided by Prof. S. Cory), and transfected cells were selected with 20 µg/ml puromycin (Sigma). For all transfected cell lines, expression of the receptors was determined by assessing the ability of cells to bind 125I-GCSF.

HCK-hprt ES cells were obtained by transfection of parental hprt- ES cells with the expression plasmid pHCK-hprt. Cells were selected in HAT medium (100 µM hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine). Individual resistant colonies were expanded and tested for HAT sensitivity after a 5-day induction of cellular differentiation in the absence of LIF. ES cells expressing chimeric constructs were obtained by electroporation of HCK-hprt cells with the 6P-IRESneo-BS-based expression constructs (Bio-Rad Gene Pulser; 270 V, 500 microfarad), followed by selection for 7 days in 175 µg/ml Geneticin (Life Technologies, Inc.). ES cells were transfected with the GCSFR-LIFR construct 1. ES cell lines expressing the full-length GCSFR were obtained by co-electroporation with the plasmid PGKneo (30). Several independently derived M1, Ba/F3, and ES cloned cell lines expressing each receptor construct were selected for further analysis.

M1 Cell Colony Assays

To quantitate the differentiation of transfected M1 clones in response to cytokine, 300 cells were cultured in 35-mm Petri dishes containing 1 ml of DMEM supplemented with 20% FCS, 0.3% agar, and 0.1 ml of serial dilutions of LIF or GCSF. Cultures were incubated at 37 °C in a humidified incubator containing 10% CO2 for 7 days. The dishes were then scored for the percentage of differentiated colonies, as judged by colonies with a halo of dispersed cells. The total number of colonies was also determined to assess the degree to which proliferation had been extinguished by the addition of the cytokine.

ES Cell Assays

The extent to which cytokine-mediated signaling prevents ES cell differentiation was determined by both morphology (as described previously; Refs. 31 and 32) and MTT staining of undifferentiated, proliferating cells after HAT selection. For the MTT assay, cells were seeded in quadruplicate cultures at 1500 cells/cm2 in gelatinized 24-well multiculture dishes (Nunc, Kamstrup, Denmark). Cells were grown for 6 days at the indicated concentration of GCSF in the absence of LIF, in medium supplemented with 2 × HAT. At this time, >95% of the morphologically differentiated cells had died. The cultures were then supplied with 0.5 mg/ml MTT and incubated for 3 h at 37 °C, after which the aspirated cultures were air-dried. The reduced MTT dye was solubilized in Me2SO, and the optical absorbance was measured at 560 nm and expressed as a percentage of the maximal absorbance measured in undifferentiated cultures maintained in 2.5 ng/ml LIF.

Proliferation Assays

The survival/proliferation of Ba/F3 cells in response to cytokine was measured in Lux 60 microwell HL-A plates (Nunc Inc., Roskilde, Denmark). Cells were washed three times in DMEM containing 20% newborn calf serum and resuspended at a concentration of 2 × 104 cells/ml in the same medium. Aliquots of 10 µl of cell suspension were placed in the culture wells with 5 µl of serial dilutions of 1 ng/ml IL-3 or 100 ng/ml GCSF. After a 2-day culture at 37 °C in a humidified incubator containing 10% CO2, viable cells were counted using an inverted microscope.

Electrophoretic Mobility Shift Assays

Assays were performed as described previously (33), using the high affinity c-sis-inducible factor binding site m67 (34). Protein extracts were prepared from M1 cells incubated with saline, 10 ng/ml LIF, or 100 ng/ml GCSF for 10 min at 37 °C. For ES cells, cultures consisting of approximately 8 × 107 undifferentiated ES cells were starved overnight in ES cell medium free of serum and LIF before being stimulated for 10 min at 37 °C with saline, 10 ng/ml LIF, or 100 ng/ml GCSF. For certain experiments, protein samples were preincubated with antibodies specific for either STAT1 (Transduction Laboratories), STAT3 (Santa Cruz Biotechnology Inc., CA), or STAT5A (specific for the C terminus, a gift from Dr. A. Mui, DNAX Research Institute, Palo Alto, CA) as described (33).

Binding Assays

Binding assays were performed essentially as described (35). Approximately 2 × 106 cells in 40 µl of RPMI 1640 medium containing 20 mM Hepes, pH 7.4, and 10% FCS were incubated for 3 h on ice with varying amounts of 125I-GCSF in the presence or the absence of 100-fold excess of unlabeled GCSF. Cell-associated and free 125I were then separated by rapid centrifugation of the cell suspension through 200 µl of FCS. The amount of 125I in the cell pellet and the supernatant was quantitated in a gamma -counter. Scatchard analysis of saturation binding isotherms were performed using the computer program LIGAND (36).


RESULTS AND DISCUSSION

Roles of LIFRalpha , gp130, and GCSFR Cytoplasmic Domains in M1 Cell Differentiation

Stimulation of M1 myeloid cells with LIF or IL-6 induces macrophage differentiation and an inhibition of cellular proliferation (5). M1 cells were transfected with either the GCSFR-LIFRalpha , GCSFR-gp130, or wild type GCSFR constructs, and the expression of these receptors was confirmed by the ability of the transfected cells to bind 125I-GCSF (Table I). The capacity of the transfected cells to differentiate in response to GCSF was assessed by semi-solid agar colony assays. Untransfected parental M1 cells failed to respond to GCSF, and all cell lines expressing the chimeric receptors responded normally to LIF (data not shown). M1 cells expressing either full-length GCSFR (Fig. 1A) or GCSFR-gp130 (Fig. 1C) responded to GCSF in a similar manner, with complete differentiation and clonal extinction at higher concentrations of cytokine. In contrast, we were unable to detect a GCSF-induced response by cells expressing GCSFR-LIFRalpha receptors, because neither differentiation nor clonal suppression of M1 cells expressing these receptors was evident (Fig. 1B). The expression of characteristic macrophage markers, including Fcgamma receptor types I and II, Mac-1, and the macrophage colony-stimulating factor receptor, was also assessed in these cells in an effort to determine whether any aspects of differentiation were induced in response to GCSF. Flow cytometric analysis demonstrated that none of these markers were up-regulated by GCSF stimulation of these cells (data not shown). Furthermore, unlike cells expressing GCSFR, no change in expression of the flk-2 receptor was detected in cells expressing GCSFR-LIFRalpha in response to GCSF, as assessed by flk-2 ligand binding assays (data not shown). Thus, by all criteria examined, no evidence for the induction of differentiation through GCSFR-LIFRalpha receptors in M1 cells could be demonstrated. Collectively, these data suggest that homodimerization of GCSFR or gp130 cytoplasmic domains, but not LIFRalpha cytoplasmic domains, is sufficient to induce macrophage differentiation in M1 cells.

Table I. Expression of transfected receptors and affinity of 125I-GCSF binding


Receptor construct M1 cells
ES cells
Ba/F3 cells
No. of receptors/cell Binding affinity No. of receptors/cell Binding affinity No. of receptors/cell Binding affinity

pM pM pM
GCSFR wild type 9359 163 NDa ND 4524 97
GCSFR-LIFR 3030 110 1060 280 963 303
GCSFR-gp130 2600 1100 850 430 763 350

a ND, not determined.


Fig. 1. Activity of chimeric receptors in M1, ES, and Ba/F3 cells. GCSFR (A, D, G, and J), GCSFR-LIFR (B, E, H, and K), and GCSFR-gp130 (C, F, I, and L) receptors were transfected into either M1, ES, or Ba/F3 cells, and their ability to transduce a GCSF-dependent signal was assessed in a variety of assays. Two independently derived clones of each transfection were examined in each assay. A-C, GCSF-induced differentiation of transfected M1 lines was assessed by soft agar colony assays. The percentage of differentiated colonies (bullet ) was scored after a 7-day culture in the indicated concentration of GCSF. The number of colonies present in each dish was determined and expressed as a percentage of the total number of colonies formed in the absence of factor (open circle ). D-I, transfected ES cells were cultured in the indicated concentration of GCSF in the absence of LIF. D-F, after a 5-day culture, the proportion of undifferentiated colonies was calculated by scoring the morphology of 300 randomly selected colonies in triplicate culture dishes. The proportion of ES colonies remaining undifferentiated after culture for 5 days in 32 pM LIF is also indicated (triangle ). G-I, MTT assay. After a 6-day culture in medium containing 2 × HAT, cultures were incubated for 3 h with MTT dye. Reduction of the MTT dye was quantitated by optical absorbance and expressed as a percentage of the maximal absorbance measured in undifferentiated cultures maintained in LIF. Results from both ES cell assays represent the mean of three independent experiments. J-L, transfected Ba/F3 cells were cultured at 200 cells/well in the presence of indicated dilutions of 100 ng/ml GCSF (bullet ) or 1 ng/ml IL-3 (open circle ). After a 2-day culture, the number of viable cells in each well was determined. All wells containing greater than 200 viable cells after the 2-day culture were scored as demonstrating a maximal response (>200).
[View Larger Version of this Image (30K GIF file)]

Roles of LIFRalpha , gp130, and GCSFR Cytoplasmic Domains in ES Cell Differentiation

In previous studies, the degree of cellular differentiation of ES cells in vitro had been quantitated primarily by morphological inspection of individual cells and colonies. To utilize a chemical selection protocol allowing for the survival of undifferentiated ES cells only, we used the observation that the murine hck gene undergoes transcriptional down-regulation following the induction of ES cell differentiation in vitro (M.E., unpublished observation). Thus, HCK-hprt ES cell lines, which contain an hprt minigene driven by an 865bp proximal hck promoter fragment, are resistant to HAT selection if they remain in an undifferentiated state. The proportion of undifferentiated, proliferating cells in an ES cell culture can then be determined by optical absorbance measurement of the reduced mitochondrial stain, MTT.

Maintenance of the pluripotency of ES cells in vitro normally requires signaling initiated by the LIF family of cytokines (6, 7, 37). ES cell lines were transfected with either full-length GCSFR or the chimeric receptor constructs, and expression of the receptors was confirmed by the ability of transfected cells to bind 125I-GCSF (Table I). In these cell lines, signaling through the endogenous LIFRalpha -gp130 heterodimer was normal, because culture in LIF maintained the cells in an undifferentiated state (Fig. 1, D, E, and F). The capacity of GCSF to substitute for LIF and retard differentiation of the transfected cells was assessed. The dose-response curve obtained with GCSF stimulation was similar for both the cell morphology (Fig. 1, D, E, and F) and MTT (Fig. 1, G, H, and I) assays, with a half-maximal effect at approximately 63 pM GCSF. Thus, signaling through homodimerized cytoplasmic domains of LIFRalpha , gp130, or GCSFR maintained up to 80% of all ES cell colonies in an undifferentiated state (Fig. 1, D-I). In contrast, parental ES cells did not respond to GCSF in either assay, indicating the absence of endogenous GCSFR expression in untransfected cells (data not shown). These data suggest that homodimerization of the cytoplasmic domains of either LIFRalpha or gp130 is sufficient to mediate a signal that maintains the pluripotentiality of ES cells in vitro. Futhermore, these data indicate that in addition to the LIFR, the GCSFR can transmit a signal that maintains the undifferentiated state of ES cells.

Roles of LIFRalpha , gp130, and GCSFR Cytoplasmic Domains in Triggering Proliferation

The potential of LIFRalpha , gp130, and GCSFR cytoplasmic domains to signal a mitogenic response was determined after introduction of the receptor constructs into the IL-3-dependent cell line, Ba/F3. Transfected cells were analyzed in a proliferation assay. As shown in Fig. 1 (J, K, and L), the full-length GCSFR was able to transduce a proliferative/survival signal comparable to that elicited through the endogenous IL-3 receptor. Ba/F3 cells expressing GCSFR-gp130 showed a weaker proliferative or survival response to GCSF, whereas no GCSF-dependent proliferation or survival was observed for cells expressing the GCSFR-LIFRalpha chimera (Fig. 1, J, K, and L). The reduced ability of gp130 homodimers to generate a GCSF response parallels the transient response of Ba/F3 cells expressing gp130 to stimulation by IL-6 and soluble IL-6 receptor (38). This may be due to reduced expression of LIFRalpha -gp130 signaling intermediates in Ba/F3 cells compared with M1 or ES cells, both of which express endogenous LIF receptors. This hypothesis is supported by preliminary results in the IL-6-dependent plasmacytoma cell line, 7TD1, that suggest that the GCSFR-LIFRalpha is active in these cells (data not shown).

Similar STAT Complexes Are Formed by Stimulation of Chimeric Receptors

Considering the differing potential of LIFRalpha , gp130, and GCSFR cytoplasmic domains to mediate cell-type specific responses, we were interested to compare the activation pattern of the Jak/STAT signaling pathway in response to receptor dimerization. To characterize the STAT complexes induced in response to GCSF, extracts of M1 and ES cells transfected with various receptor constructs were examined in electrophoretic mobility shift assays, using the high affinity c-sis-inducible factor binding sequence, m67, as a probe (34). All DNA-protein interactions were specifically competed by an excess of unlabeled m67 probe (data not shown). Three main complexes were induced in M1 cells stimulated with LIF through the activation of the endogenous LIFR (Fig. 2A). A similar pattern was observed upon GCSF stimulation of M1 cells expressing GCSFR-gp130 (Fig. 2A) and for GCSF stimulation of M1 cells expressing wild type GCSFR (Fig. 2B). In contrast, no m67-binding complexes were formed in response to GCSF in M1 cells expressing GCSFR-LIFRalpha nor in parental M1 cells (Fig. 2A). Hence, activation of m67-binding complexes correlated with the expression of active cell surface receptors, suggesting that STAT molecules may act as downstream effectors of the response.


Fig. 2. Analysis of DNA-binding complexes induced by cytokine stimulation of transfected cells. A, electrophoretic mobility shift assays of transfected M1 cells stimulated with either saline (-), LIF (L), or GCSF (G). M1-P refers to the untransfected parental M1 cell line. DNA-protein complexes are indicated by arrows. Extracts from M1 cells (B) and ES cells (C) were analyzed in electrophoretic mobility shift assays in the presence (+) or the absence (-) of the indicated antibodies and stimuli. The composition of the STAT complexes is indicated at the left of the figure.
[View Larger Version of this Image (44K GIF file)]

The molecular nature of the STAT complexes was further investigated by the addition of antibodies specific for individual STAT proteins. The pretreatment of M1 cell extracts with antibodies specific for STAT1 supershifted the two minor lower bands to slower migrating complexes, indicating that these bands contain STAT1 (Fig. 2B). Similarly, the upper two bands were supershifted by the addition of an antibody recognizing STAT3 (Fig. 2B). The most slowly migrating DNA complex was also affected by binding of an anti-STAT5A antibody, suggesting that this complex comprises a STAT3-STAT5A heterodimer. The pattern and composition of m67-binding complexes induced by either GCSF, via the introduced receptors, or LIF stimulation, through endogenous LIF receptors, were identical for M1 cells expressing either GCSFR-gp130 or wild type GCSFR (Fig. 2B). The same signaling molecules were activated by either LIF or GCSF stimulation of ES cells expressing GCSFR-gp130 (Fig. 2C). Furthermore, identical complexes were induced by GCSF stimulation of ES cells signaling through GCSFR-LIFRalpha (Fig. 2C). The level of STAT activation induced by this chimeric receptor was comparatively weaker, despite its comparable capacity to retard differentiation (Fig. 1, D-I).

It is clear from this study that despite a high degree of sequence similarity, the signaling potential of the cytoplasmic domains of LIFRalpha , gp130, and GCSFR differ depending on the cell type as well as the type of biological response initiated. Differences in the signal transduction pathways triggered by gp130 homodimers and gp130-LIFRalpha heterodimers have previously been suggested by studies in which overexpression of SCL in M1 cells inhibited the response to LIF and OSM, which use gp130-LIFRalpha heterodimers, but did not affect signaling through the IL-6 receptor, which uses gp130 homodimers (18, 19). LIFRalpha alone may not be sufficient for transducing a differentiative signal in M1 cells nor for induction of a proliferation/survival signal in Ba/F3 cells, because homodimerized LIFRalpha cytoplasmic domains were unable to signal these responses independently of gp130. However, homodimers of either LIFRalpha or gp130 cytoplasmic domains were able to deliver the signal to block differentiation in ES cells. In addition, a previous report has demonstrated that either of these cytoplasmic domains can induce an acute phase response in hepatoma cells and mediate signaling in neuronal cells when activated as homodimers (22).

The cell-specific differences in activity described here are unlikely to be due to differences in the level of receptor expression, because Scatchard analyses of binding isotherms indicated a similar level of expression of the chimeric receptors in each cell type and a comparable binding affinity for GCSF (Table I). Because none of the three cell lines express detectable levels of endogenous full-length GCSFR, dimer formation between the extracellular domains of endogenous and introduced receptor subunits should not occur. Furthermore, cooperativity between the cytoplasmic domains of introduced receptor subunits and endogenous LIFRalpha or gp130 is unlikely, given that the GCSFR-LIFRalpha receptor is unable to signal in M1 cells, which contain both endogenous LIFRalpha and gp130.

The observed differences in signaling potential of the homodimeric cytoplasmic domains may be due to either quantitative or qualitative differences in the signaling molecules activated. First, different biological responses may require a different threshold of STAT activation to be attained, with certain responses requiring a higher level of activation. The activation of STAT molecules by homodimeric LIFRalpha cytoplasmic domains may fail to reach the required threshold in M1 or Ba/F3 cells for a biological response to occur, perhaps due to a reduced efficiency of the LIFRalpha chain to activate STATs or a reduced pool size of signaling intermediates. The number of available STAT molecules in ES cells may be greater than that in either M1 or Ba/F3 cells. Although the LIFRalpha chain may be less efficient at activating STATs, the increased availability of STATs, coupled with a lower threshold requirement for biological activity in these cells, could explain the ability of the GCSFR-LIFRalpha receptor to signal in ES cells.

Alternatively, different signaling intermediates may be activated by the different receptor subunits. Activation of pathways necessary for M1 cell differentiation and Ba/F3 proliferation may require gp130 cytoplasmic sequences, whereas both LIFRalpha and gp130 may be able to interact with the specific cytoplasmic intermediates required for signal transduction in ES, hepatoma, and neuronal cells. Verification of this model would require the identification of the relevant signaling pathways. In either case, the results described here clearly show that LIFRalpha homodimers are less efficient than either gp130 or GCSFR homodimers in signaling biological responses. Further investigation of the signaling molecules activated by LIFRalpha and gp130 is needed to fully document the different signaling potentials of these receptor subunits.


FOOTNOTES

*   This work was supported by the Anti-Cancer Council of Victoria, Melbourne, Australia; AMRAD Operations Pty. Ltd., Melbourne, Australia; the National Health and Medical Research Council, Canberra, Australia; the J. D. and L. Harris Trust; National Institutes of Health Grant Grant CA-22556; and the Australian Federal Government Cooperative Research Centres Program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
par    Supported by a Queen Elizabeth II Postdoctoral Fellowship from the Australian Research Council.
**   To whom correspondence should be addressed. Tel.: 61-3-9347-3155; Fax: 61-3-9347-1938; E-mail; ernst{at}licre.ludwig.edu.au.
1   The abbreviations used are: LIF, leukemia inhibitory factor; LIFR, LIF receptor; LIFRalpha , LIFR alpha -chain; ES, embryonic stem; IL, interleukin; OSM, oncostatin M; CNTF, ciliary neurotrophic factor; GCSF, granulocyte colony-stimulating factor; GCSFR, GCSF receptor; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; MTT, 3-[4,5-dimethyldiazol-2-yl]-2,5-diphenyltetrazolium bromide.

ACKNOWLEDGEMENTS

We thank L. Di Rago, S. Mifsud, and L. Paradiso for excellent technical assistance. The following are thanked for generously providing reagents: Prof. S. Cory (pPGKPuropA), Dr. A. Mui (anti-STAT5A antibody), Prof. S. Nagata (human GCSFR cDNA clone), AMGEN (rhGCSF), and Dr. J.-G. Zhang and C. McFarlane (mGCSF).


REFERENCES

  1. Nicola, N. A., and Hilton, D. J. (1997) Growth Factors and Cytokines in Health and Disease, Vol. 23, pp. 605-660, JAI Press, Greenwich, CT
  2. Leary, A. G., Wong, G. G., Clark, S. C., Smith, A. G., and Ogawa, M. (1990) Blood 75, 1960-1964 [Abstract]
  3. Metcalf, D., Hilton, D. J., and Nicola, N. A. (1988) Leukemia 2, 216-221 [Medline] [Order article via Infotrieve]
  4. Baumann, H., and Wong, G. G. (1989) J. Immunol. 143, 1163-1167 [Abstract/Free Full Text]
  5. Hilton, D. J., Nicola, N. A., Gough, N. M., and Metcalf, D. (1988) J. Biol. Chem. 263, 9238-9243 [Abstract/Free Full Text]
  6. Smith, A. G., Heath, J. K., Donaldson, D. D., Wong, G. G, Moreau, J., Stahl, M., and Rogers, D. (1988) Nature 336, 688-690 [CrossRef][Medline] [Order article via Infotrieve]
  7. Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gearing, D. P., Wagner, E. F., Metcalf, D., Nicola, N. A., and Gough, N. M. (1988) Nature 336, 684-687 [CrossRef][Medline] [Order article via Infotrieve]
  8. Gearing, D. P., Comeau, M. R., Friend, D. J., Gimpel, S. D., Thut, C. J., McGourty, J., Brasher, K. K., King, J. A., Gillis, S., Mosley, B., Ziegler, S. F., and Cosman, D. (1992) Science 255, 1434-1437 [Medline] [Order article via Infotrieve]
  9. Ip, N. Y., Nye, S. H., Boulton, T. G., Davis, S., Taga, T., Li, Y., Birren, S. J., Yasukawa, K., Kishimoto, T., Anderson, D. J., and Stahl, N. (1992) Cell 69, 1121-1132 [Medline] [Order article via Infotrieve]
  10. Yin, T., Taga, T., Tsang, M. L.-S., Yasukawa, K., Kishimoto, T., and Yang, Y.-C. (1993) J. Immunol. 151, 2555-2561 [Abstract/Free Full Text]
  11. Hilton, D. J., Hilton, A. A., Raicevic, A., Rakar, S., Harrison-Smith, M., Gough, N. M., Begley, C. G., Metcalf, D., Nicola, N. A., and Willson, T. A. (1994) EMBO J. 13, 4765-4775 [Abstract]
  12. Kishimoto, T., Akira, S., Narazaki, M., and Taga, T. (1995) Blood 86, 1243-1254 [Free Full Text]
  13. Mosley, B., De Imus, C., Friend, D., Boiani, N., Thoma, B., Park, L. S., and Cosman, D. (1996) J. Biol. Chem. 271, 32635-32643 [Abstract/Free Full Text]
  14. Gearing, D. P., Thut, C. J., VandenBos, T., Gimpel, S. D., Delaney, P. B., King, J., Price, V., Cosman, D., and Beckman, M. P. (1991) EMBO J. 10, 2839-2848 [Abstract]
  15. Baumann, H., Ziegler, S. F., Mosley, B., Morella, K. K., Pajovic, S., and Gearing, D. P. (1993) J. Biol. Chem. 268, 8414-8417 [Abstract/Free Full Text]
  16. Boulton, T. G., Stahl, N., and Yancopoulos, G. D. (1994) J. Biol. Chem. 269, 11648-11655 [Abstract/Free Full Text]
  17. Stahl, N., Boulton, T. G., Farruggella, T., Ip, N. Y., Davis, S., Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Barbieri, G., Pellegrini, S., Ihle, J. N., and Yancopoulos, G. D. (1994) Science 263, 92-94 [Medline] [Order article via Infotrieve]
  18. Tanigawa, T., Elwood, N., Metcalf, D., Cary, D., DeLuca, E., Nicola, N. A., and Begley, C. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7864-7868 [Abstract/Free Full Text]
  19. Tanigawa, T., Nicola, N. A., McArthur, G. A., Strasser, A., and Begley, C. G. (1995) Blood 85, 379-390 [Abstract/Free Full Text]
  20. Ishizaka-Ikeda, E., Fukunaga, R., Wood, W. I., Goeddel, D. V., and Nagata, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 123-127 [Abstract]
  21. Yamanaka, Y., Nakajima, K., Fukada, T., Hibi, M., and Hirano, T. (1996) EMBO J. 15, 1557-1565 [Abstract]
  22. Baumann, H., Symes, A. J., Comeau, M. R., Morella, K. K., Wang, Y., Friend, D., Ziegler, S. F., Fink, J. S., and Gearing, D. P. (1994) Mol. Cell. Biol. 14, 138-146 [Abstract]
  23. Hooper, M., Hardy, K., Handyside, A., Hunter, S., and Monk, M. (1987) Nature 326, 292-295 [CrossRef][Medline] [Order article via Infotrieve]
  24. Gearing, D. P., Nicola, N. A., Metcalf, D., Foote, S., Willson, T. A., Gough, N. M., and Williams, L. (1989) BioTechnology 7, 1157-1161
  25. Cregg, J. M., Barringer, K. J., Hessler, A. Y., and Madden, K. R. (1985) Mol. Cell. Biol. 5, 3376-3385 [Medline] [Order article via Infotrieve]
  26. Fukunaga, R., Ishizaka-Ikeda, E., Seto, Y., and Nagata, S. (1990) Cell 61, 341-350 [Medline] [Order article via Infotrieve]
  27. Mountford, P., Zevnik, B., Duwel, A., Nichols, J., Li, M., Dani, C., Robertson, M., Chambers, I., and Smith, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4303-4307 [Abstract]
  28. Mizushima, S., and Nagata, S. (1990) Nucleic Acids Res. 18, 5322 [Medline] [Order article via Infotrieve]
  29. Lock, P., Stanley, E., Holtzman, D. A., and Dunn, A. R. (1990) Mol. Cell. Biol. 10, 4602-4811
  30. Tybulewic, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T., and Mulligan, R. C. (1991) Cell 65, 1153-1163 [Medline] [Order article via Infotrieve]
  31. Ernst, M., Gearing, D. P., and Dunn, A. R. (1994) EMBO J. 13, 1574-1584 [Abstract]
  32. Ernst, M., Oates, A., and Dunn, A. R. (1996) J. Biol. Chem. 271, 30136-30143 [Abstract/Free Full Text]
  33. Novak, U., Harpur, A. G., Paradiso, L., Kanagasundaram, V., Jaworowski, A., Wilks, A. F., and Hamilton, J. A. (1995) Blood 86, 2948-2956 [Abstract/Free Full Text]
  34. Wakao, H., Gouilleux, F., and Groner, B. (1994) EMBO J. 13, 2182-2191 [Abstract]
  35. Hilton, D. J., and Nicola, N. A. (1992) J. Biol. Chem. 267, 10238-10247 [Abstract/Free Full Text]
  36. Munson, P. J., and Rodbard, D. (1980) Anal. Biochem. 107, 220-239 [Medline] [Order article via Infotrieve]
  37. Nichols, J., Chambers, I., and Smith, A. (1994) Exp. Cell Res. 215, 237-239 [CrossRef][Medline] [Order article via Infotrieve]
  38. Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., Taga, T., and Kishimoto, T. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11349-11353 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.